Roschier advised TILT Biotherapeutics in connection with their EUR 22 million financing round
TILT Biotherapeutics Ltd, a Finnish clinical-stage biotechnology company developing cancer immunotherapies, has secured EUR 22 million in new funding to advance phase II oncology immunotherapy trials. Roschier represented TILT in the investment round comprising multiple closings.
The final closing of the financing round follows the first close of EUR 10 million in June 2022, led by Lifeline Ventures, an early-stage venture capital firm supporting the growth of category-leading companies.
The remaining EUR 12 million include an equity investment of EUR 5.9 million from the European Innovation Council (EIC) Fund, an EUR 2.1 million grant under EIC’s Accelerator programme, and equity investments of EUR 3 million from Stephen Industries Inc Oy and EUR 1 million from Acme Investments SPF S.a.r.l.
Roschier’s core advisory team comprised Tero Jormanainen, Wiljami Siitonen, Sabina Hautaviita and Johanna Flythström.